Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as an injectable solution for intravenous use. It shortens T1 relaxation times, thereby increasing signal intensity on magnetic resonance imaging and is employed to improve visualization of the central nervous system, liver and cardiovascular structures.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, tertiary care centers and imaging facilities worldwide, with regulatory‑approved quality systems. Our distribution network ensures timely delivery and compliance with local import requirements.

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to enhance visualization of specific organ systems.

- Central nervous system imaging: improves lesion detection and anatomical detail in brain and spinal cord MRI. - Liver imaging: enhances lesion conspicuity and vascular phase assessment in hepatic MRI. - Cardiovascular imaging: provides clearer delineation of cardiac chambers, vessels and perfusion during MRI studies.

Adverse reactions to Multihance may range from mild, transient events to rare but serious conditions.

Common Side Effects: - Nausea: mild, transient feeling of queasiness. - Headache: temporary discomfort following injection. - Injection site pain: brief soreness or burning at the catheter site. - Warm sensation: fleeting feeling of warmth or metallic taste. - Vomiting: occasional episodes after injection. - Dizziness: brief light‑headedness.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis (NSF): a fibrotic disorder in patients with severe renal impairment. - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical intervention. - Cardiovascular collapse: hypotension or cardiac arrest occurring shortly after administration. - Gadolinium retention: long‑term deposition in brain or bone tissues, of uncertain clinical significance.

Prior to using Multihance, several safety considerations should be evaluated to minimize risk.

- Assess renal function: evaluate eGFR and avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). - Review allergy history: contraindicated in individuals with known hypersensitivity to gadolinium agents. - Pregnancy and lactation: use only if essential, as safety data are limited. - Pediatric use: dose adjustment and careful monitoring are required for children. - Concomitant nephrotoxic drugs: consider reducing exposure to agents that may worsen renal function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other medicines or conditions that affect renal clearance or immune response.

Major Interactions (Avoid): - Renal toxic agents (e.g., high‑dose NSAIDs, aminoglycosides): increase risk of renal impairment and NSF. - Chelating therapy (e.g., deferoxamine): may bind gadolinium and reduce imaging efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt hemodynamic changes during injection. - Hydration protocols: adequate fluid administration can mitigate renal risk and should be coordinated. - Calcium channel blockers: occasional reports of altered contrast distribution; monitor patient response.